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1. Abstract 
Objective: to describe clinical and imaging findings in a group of patients affected by non-syndromic 
deafness A9 (DFNA9), using advanced Magnetic Resonance (MR) imaging with three-dimensional 
(3D) Fluid-Attenuated Inversion Recovery (FLAIR) sequence. 
Method: a retrospective case review was conducted in a tertiary referral center in Italy. Four 
sequential adult DFNA9-affected patients, who had undergone MR imaging at our Department 
between January 2017 and June 2018, were enrolled (Male = 2, Female = 2; median age: 65,6yr; 8 
diseased ears analyzed). Three patients were relatives; the fourth was unrelated. The main outcome 
measures - age, sex, records of audiological and vestibular testing, genetic assessment, MR imaging 
findings - were analyzed. 
Results: All subjects suffered from bilateral progressive sensorineural hearing loss, more severe on 
the high frequencies and typical clinical pattern of bilateral chronic degenerative cochleo-vestibular 
deficit. Aural fullness was reported at the onset of the disease. All patient revealed a pathogenic 
heterozygous mutation in the Limulus factor C, Coch- 5b2 and Lgl1 domain (LCCL) of cochlin. None of 
the patients showed a significant vestibular and cochlear endolymphatic hydrops at MR imaging, 
while high bilateral contrast enhancement on 4hs-delayed postcontrast 3D-FLAIR sequence was 
observed in all ears. 
Conclusions: increased perilymph enhancement on 4hs-delayed postcontrast 3D- FLAIR sequence is 
the common imaging feature of DFNA9 ears, suggesting that blood-labyrinthine barrier (BLB) 
breakdown may play the main role in the pathophysiology of this disease. Significant hydrops has 
been excluded by MR imaging. This finding might be clinically useful in differentiating DFNA9 disease 
from other pathologies with similar clinical findings like Ménière’s disease.  
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2. Introduction 
Non-syndromic deafness A9 (DFNA9) is a cause of autosomal dominant late-onset sensorineural 
hearing loss (SNHL) associated with progressive bilateral vestibular deterioration [Manolis et al., 
1996; Kemperman et al., 2005]. The disease starts with a high-frequency hearing loss and progresses 
to a poor hearing performance in the 6th and 7th decades  [Manolis et al., 1996; Fransen, and Van 
Camp, 1999; Lemaire et al., 2003; Bischoff et al., 2005; Kemperman et al., 2005; Hildebrand et al., 
2010]. Given the rarity of the disease [Fransen and Van Camp, 1999; Usami et al., 2003; Chen et al., 
2013] and its clinical presentation characterized by fluctuating hearing loss accompanied with 
intermittent vertigo and dizziness, aural fullness and tinnitus, DFNA9 can sometimes be 
misdiagnosed as Ménière’s disease or dehiscent superior semicircular canal syndrome [De Kok et al., 
1999; Lemaire et al., 2003; Hildebrand et al., 2009]. Mutations in the COCH (Coagulation Factor C 
Homology) gene, found on the long arm of chromosome 14 (14q12-q13), has been linked to the 
development of the disease [Manolis et al., 1996]. The gene encodes for the cochlin protein, which is 
highly expressed in the cochlea and in the vestibular system [Robertson et al., 1998; Li et al., 2005; 
Robertson et al., 2006].  The function of cochlin has yet to be fully understood; it is believed to assist 
the local immunological response and to provide structural support in the inner ear [Bhattacharya, 
2006; Py et al., 2013; Bae et al., 2014]. Although interest is increasing in the genomics and 
pathophysiology underlying COCH-related disease and DFNA9, information about the morphological 
appearance at imaging are limited.  Recent contrast-enhanced Magnetic Resonance (MR) imaging, 
with three-dimensional (3D) Fluid-Attenuated Inversion Recovery (FLAIR) sequence, allows in-vivo 
assessment of the Blood-Labyrinthine Barrier (BLB) permeability, of the content and relative volume 
of the perilymphatic compartment and of the morphology of the endolymphatic space (ES) in 
humans [Conte et al., 2017]. Our aim was to describe the imaging findings in a group of consecutive 
patients affected by DFNA9, using advanced MR imaging with 3D-FLAIR sequence. 
3. Materials and Methods 
3.1 Subjects 
This study was approved by the Institutional Review Board of Fondazione IRCCS Ca’ Granda Ospedale 
Maggiore Policlinico of Milan, Italy (Protocol N. 473_2018, accepted 19th June 2018). Informed 
consent was waived. We retrospectively enrolled all sequential patients affected by DFNA9, who had 
undergone MR imaging at our Department between January 2017 and June 2018. We also collected 
24 consecutive MR imaging scans of normal ears (males = 13, females = 11; age range: 25-74 years, 
median age: 53 years) obtained at our Department between July 2016 and December 2017, in order 
to constitute a control group. These “normal” ears were represented by the contralateral ear of a 
group of unilateral sudden deafness patients, diagnosed according to the American Academy of 
Otolaryngology - Head and Neck Surgery criteria [American Speech-Language-Hearing Association. 
Guidelines for Audiologic Screening [Guidelines], 1997], who had undergone MRI. From an otological 
viewpoint, ears were defined as normal according to the following criteria: 1) no history of otological 
disorders (either  middle or inner ear pathology), no report of previous ear surgery and/or no history 
of previous or current vertigo episodes and/or dizziness,  as evidenced by the patient’s medical 
record; 2) normal results at the audiological evaluation with otomicroscopy, pure-tone audiometry, 
immittance audiometry, transient-otoacoustic emissions, and speech audiometry 3) no pathological 
findings on MRI. 
3.2 Audiological and vestibular assessment 
The measurements were all conducted in a sound-attenuated booth fulfilling the requirements of ISO 
8253-3 (2012), at the Audiology Unit, Department of Surgical Sciences, University of Milan, Milan, 
Italy.   
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After gathering all relevant clinical information about the onset and progression of hearing loss and 
any concurrent balance disorders, all subjects underwent the following battery of tests: 
● otomicroscopy 
● pure-tone audiometry (Amplaid A321, Resonance, Gazzaniga, Italy) with measurement of air 
conduction (AC) thresholds at all octave frequencies between 125 and 8000 Hz and of bone 
conduction (BC) thresholds between 250 and 4000 Hz; thresholds were reported as PTA4 = 
pure tone average of 0.5-1-2-4 kHz  
● middle ear impedance testing  
● transiently evoked otoacoustic emissions (TEOAE) (Grason-Stadler Audera, Eden Prairie MN, 
USA)  
● speech perception tests: disyllabic words recognition (WRS) delivered to each ear via TDH49 
ear muffs (Amplaid A321, Resonance, Gazzaniga, Italy). 
All patients with DFNA9 underwent also a vestibular assessment by means of: 
● cervical and ocular vestibular evoked myogenic potentials (cVEMPS/oVEMPS, Amplaid MK22, 
Milano, Italy),  
● static stabilometry (SVEP system 6.0, Amplaid, Politecnica Modena, Italy) at 5 Hz with eyes 
opened and closed, with and without foam pads (Di Berardino F., et al. The assessment of 
static posturography’s variability and the sensorial ratios by the use of foam pads. Gait and 
Posture 2009: 29: 1;158-160). 
● bithermal caloric testing, according to the Hallpike technique and Jongkee’s formulae 
● the recording of the vestibulo-ocular reflex (VOR) by video-oculography (VN 525, 
Interacoustics, Middelfart, Denmark) using a sinusoidal rotatory chair testing (burst of 
sinewave for 20 s) with 30°/sec and 60°/sec peak chair velocity 
● video head impulse test (v-HIT) (Otometrics Natus, Taastrup, Denmark). We used a gain cut-
off value of 0.8 for the vHIT and presence of correction saccades to define an abnormal 
vestibular-ocular reflex on the horizontal semicircular canals. 
 
3.3 Genetic assessment 
DNA was extracted from peripheral blood samples using QIAamp DNA Mini Kit following the protocol 
provided by the manufacturer. Library preparation was performed with the TruSight One sequencing 
panel (Illumina, San Diego, USA), which enriches the sample for about 4,800 genes of clinical 
relevance (only exonic region). Massively parallel sequencing was conducted with NextSeq 5500 
(Illumina, USA), Paired End method (2X151cycles). BaseSpace software (Illumina) allowed us to 
generate bam, bam.bai and vcf files and VariantStudio software® (Illumina©) to analyze the files 
focused on 80 genes harboring known deafness-causing mutations including DFNA9. GRCh37 (hg19) 
was used as the reference sequence for mapping and variant calling. Databases used for analysis and 
variant annotation include the Online Mendelian Inheritance in Man (OMIM), Human Gene Mutation 
Database, ClinVar, Single Nucleotide Polymorphism database (dbSNP), Exome Aggregation 
Consortium (ExAC) and Exome Sequencing Project, with a minor allele frequency cut-off of 1%. 
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3.4 MR imaging acquisition and assessment 
All patients were imaged on a 3 Tesla scanner (Achieva, Philips Healthcare, Netherlands) using a 32-
channel head coil. The imaging protocol consisted of sequences for both the whole brain and 
temporal bone assessment, as recommended in MR imaging of SSHL [Conte et al., 2018 a]. In 
addition, after intravenous contrast-agent administration, the protocol included 4 hours delayed 
post-contrast MR imaging for the evaluation of the membranous labyrinth as accepted in the recent 
literature [Nakashima et al., 2009; Conte et al., 2017; Conte et al., 2018 b; Conte et al., 2018 c]. 
Contrast-agent (Gadoteridol, Prohance™, Bracco Diagnostic Inc., Milan, Italy) was administered 
intravenously at the recommended dose (0.2 mmol/kg). MR protocol parameters are listed in Table 
1. A neuroradiologist with 6 years of experience in otoradiology and a senior radiology resident, 
assessed MR images in consensus. For each ear the readers assessed: 1) on T2 weighted three-
dimensional (3D) steady-state free precession (FFSP) sequence the traverse section of the cochlear 
nerve on the para-sagittal plane perpendicular to the internal auditory canal at the level of the 
fundus, defining it as “normal” if larger than the facial nerve, “hypoplastic” if equal or less [Heining et 
al., 2017] (Figure 1a, b); 2) the cochlear signal on precontrast T1-weighted fast spin echo (T1 FSE), 3D 
T2-FFSP and 3D-FLAIR; pre-contrast T1 FSE and 3D-FLAIR sequences were performed to evaluate the 
eventual presence of blood product and/or proteinaceous content in the cochlea respectively; the 
enhancement on 4hs-delayed postcontrast 3D-FLAIR sequence was measured as the ratio between 
the mean value of a polygonal region-of-interest (ROI) drawn on the middle turn the cochlea (ROI 
area ≅ 6mm3)  and the mean value of a circular ROI drawn on the cerebrospinal fluid (CSF) at the 
level of the cerebellar-pontine angle (Figure 2); these ratios were assessed for normal distribution 
with Shapiro-Wilk test and further compared with the distribution of the corresponding ratios 
calculated in the 24 healthy ears.  Values were defined as not normal if felt outside ± 2 standard 
deviations from the mean, in particular “decreased” if below 2 standard deviations from the mean 
(2.5 percentile), “increased” when above 2 standard deviations from the mean (97.5 percentiles), 
“normal” if comprised between 2 standard deviations from the mean (between the 2.5 and 97.5 
percentiles); 3) the presence of vestibular (vEH) or cochlear endolymphatic hydrops (cEH) defined 
using the Nakashima’s quantitative method on 4hs-delayed postcontrast 3D-FLAIR sequence 
[Nakashima et al., 2009] (Figure 2). 
4. Results 
Four DFNA9-affected patients were enrolled (male = 2, female = 2; median age: 65,6yr) with a total 
of 8 diseased ears analyzed. Three patients were relatives; the fourth was unrelated and had no 
relatives to be tested. Control SSHL group counted 24 patients (males = 13, females = 11; median 
age: 53) with total of 24 healthy ears analyzed. All selected DFNA9 patients were white Caucasians, 
and for all of them, NGS revealed a pathogenic heterozygous mutation in the Limulus factor C, Coch-
5b2 and Lgl1 domain (LCCL) of cochlin. The genetic profile of DFNA9 patients is reported in Table 2; 
the missense heterozygous mutation in the COCH gene (NM_004086.2) was G88A in three relatives 
and W117R in the other patient. The results of the audiological assessment are summarized in Table 
3.  All the DFNA9 subjects suffered from bilateral progressive SNHL, more severe on the high 
frequencies, tinnitus, and bilateral symmetrical labyrinthine hyporeflexia, embodying the typical 
clinical pattern of bilateral chronic degenerative cochleo-vestibular deficit. All patients complained of 
aural fullness from the onset of the disease, but none of them reported fluctuating hearing loss. The 
degree of hearing loss was moderately severe in two (one of them reported environmental exposure 
to acoustic trauma) and severe in two others. TEOAE were not detectable in all cases. Vestibular 
dysfunction was observed in all DFNA9 patients: it was characterized by weakened bilateral 
semicircular canal function (areflexia in one out of four patients) by both VOR, v-HIT and caloric 
testing. Despite the poor or very poor bilateral response at caloric testing, the two males (patient #2 
and 4) did not complain of vertigo spells and showed static posturography values within the normal 
range without foam pads, higher values showing static instability were found on foam pads especially 
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at closed eyes. The acoustic reflexes were elicited with low thresholds (positive Metz test), 
supporting a probable cochlear origin of the hearing loss.  Patients #2, 3, 4 benefited from bilateral 
hearing aids (HA) with customized earmolds.  A more severe clinical pattern was observed in patient 
#1, who showed bilateral severe to profound SNHL with a longer duration of the disease and a higher 
frequency of vertigo spells and of episodes of sudden drops of hearing.  She obtained limited benefit 
by HA, thus underwent cochlear implantation (CI) in the right ear at our Department in December 
2017. She retained her HA in the ear opposite to the CI, achieving a significant improvement of the 
perceptive abilities already after 6 months of bimodal hearing. The results of the imaging assessment 
are summarized in Table 4. Patient #1 was the only one to show a high precontrast T1-signal intensity 
in the left ear. The same patient had a high precontrast FLAIR signal intensity in both ears. Another 
patient (#3) showed high precontrast FLAIR signal intensity in the right ear and hypoplasia of the 
contralateral cochlear nerve. Patient #4 showed hypoplasia of the left cochlear nerve but no other 
signal abnormalities on pre-contrast imaging. As in the control group, none of the DFNA9 patients 
showed a significant vEH and cEH. Conversely, all DFNA9 ears showed a high bilateral contrast 
enhancement on 4hs-delayed postcontrast 3D-FLAIR sequence (Figure 2 A). 
5. Discussion 
Our study showed that the common imaging finding in DFNA9 ears is the higher enhancement of the 
perilymph, in both cochlear and vestibular spaces, on 4hs-delayed post-contrast 3D FLAIR sequence. 
In addition, an increased signal on precontrast 3D-FLAIR was also observed in our patient #1 and #3; 
patient #1 also showed increased signal on precontrast T1-weighted sequence. No signs of 
endolymphatic hydrops were identified in any of the 4 patients. At the best of our knowledge there 
are no studies that have already investigated MR findings of DFNA9 ears by a 3 Tesla scanner and 
using pre- and postcontrast 3D-FLAIR sequences, which has been demonstrated to be an emerging 
technique able to add new insights about different inner ear pathologies, such as sudden hearing loss 
and Ménière’s disease [Conte et al., 2017]. Another study had attempted to assess the morphology 
of DFNA9 ears by computed tomography and by MRI using classic heavily-T2 MR sequence, which is, 
unfortunately, less sensitive in detecting the changes in inner ear structures [De Varebeke et al., 
2014].  
The increased enhancement of the perilymph on 4hs-delayed postcontrast 3D-FLAIR sequence 
suggests the breakdown of the blood-labyrinthine barrier (BLB). The BLB is crucial for the 
maintenance of inner ear fluid ionic homeostasis, preventing the entry of toxic substances into the 
inner ear. By studying pharmacokinetics of drugs and their distribution from the systemic 
circulation into the fluids of the inner ear, it has been demonstrated that BLB is highly selective 
and that the composition of the inner ear fluids is regulated and markedly different from that of 
blood or of other fluids such as cerebrospinal fluid [Juhn et al., 2001; Ishiyama et al., 2017]. It is well 
known that after its intravenous administration, the contrast-agent starts physiologically to 
accumulate in the perilymph, but not in the endolymph, crossing the BLB and reaching the maximum 
concentration at about 4.5 hours from the administration [Naganawa et al., 2012]. As a consequence, 
post-contrast MR imaging acquired at about 4-5 hours can distinguish the membranous labyrinth 
(hypointense) from the surrounding perilymph (hyperintense). In normal conditions the progressive 
enhancement of the perilymph should be symmetric, while an asymmetric enhancement at early 
and/or delayed post-contrast sequences indicates the BLB breakdown on the affected side [Berrettini 
et al., 2013; Pakdaman et al., 2016; Conte et al., 2017; Conte et al 2018].  In the three ears in which 
the enhancement is more evident (Table 4), the association of spontaneously increased signal on pre-
contrast FLAIR suggests that the BLB breakdown caused the accumulation of proteinaceous material 
in the perilymph, among which, possibly also cochlin. Cochlin, expressed in the osseous spiral lamina, 
spiral ligament, limbus, and stroma of the maculae and cristae [Robertson et al., 1998; Li et al., 2005; 
Robertson et al., 2006], is a secreted protein with three functional domains (LCCL domain, vWFA1, 
vWFA2) likely to be involved in antibody-independent host defense mechanisms [Bhattacharya, 
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2006; Py et al., 2013; Bae et al., 2014] and to be associated with extracellular matrix proteins, 
typically fibrillar collagens [Khetarpal, 2000; Nagy et al., 2008;]. Histopathologic studies revealed that 
in DFNA9 patients cochlin protein aggregates in the extracellular matrix, altering protein to protein 
interactions [Robertson et al., 1998; Merchant et al., 2000; Khetarpal, 2000; Street et al., 2005; 
Bhattacharya, 2006; Robertson et al., 2006; Bae et al., 2014], and possibly interfering with ionic 
homeostasis; it also accumulates in the spiral ligament, in the distal osseous spiral lamina, at the base 
of the spiral limbus and in mesenchymal tissue at the base of the vestibular neuroepithelium 
[Burgess et al., 2016]. An electron microscopic study by Khetarpal et al. [2000] demonstrated that 
mutated cochlin can alter normal interaction between fibrillar collagen type II and extracellular 
matrix in the spiral ligament, promoting collagen degradation [Khetarpal, 2000]. A direct toxic effect 
of the deposited material may cause severe degeneration of multiple cytologic elements [Merchant 
et al., 2000; Robertson et al., 2006; Burgess et al., 2016]. Moreover, the cochlin von Willebrand 
domains have been suggested to play a key role in increasing shear-induced platelet aggregation 
[Bhattacharya, 2006], possibly resulting in vascular disease with subsequent tissue degeneration. The 
direct toxic effect of protein aggregates and the induced vascular degeneration may play a causative 
role in the BLB breakdown. Interestingly, endolymphatic hydrops was not a prominent feature 
DFNA9 affected patient, despite vestibular symptoms (patient #1 and 2), bilateral hyporeflexia 
(patient #1, 3 and 4) or areflexia (patient #2), and abnormal vestibular reflexes. This finding seems to 
suggest that the pathogenesis and the progression of otovestibular symptoms in DFNA9 are not 
determined by vestibular endolymphatic hydrops. Likewise, cochlear hydrops should not be 
addressed as the culprit behind progressive SNHL. DFNA9 has often been confused with Ménière’s 
disease, due to similar clinical presentation especially in early stages [De Kok et al., 1999; Lemaire et 
al., 2003; Hildebrand et al., 2009]. In contrast, DFNA9 does not show signs of EH, which is instead a 
prominent pathophysiologic feature of Ménière’s disease [Nakashima et al., 2009; Baráth et al., 
2014]. As far as we know, this is the first study providing imaging evidence of absence of cEH and 
vEH, in agreement and support to a previous report by Usami et al. [2003] who underlined the 
discrepancies between DFNA9 and Ménière’s disease [Usami et al., 2003]. Our patients #3 and #4 
showed unilateral hypoplasia of the cochlear nerve a finding which was not mentioned in previous 
DFNA9 studies. Hypoplasia of the cochlear nerve has been linked to profound deafness and reduced 
spiral ganglion cell count [Nadol and Xu, 1992; Kujawa and Liberman, 2009]. Interestingly, the 
reduced cochlear nerve diameter did not correlate with worse clinical performance (patient #3 and 
4). It should be kept in mind that the variability of diameters of cochlear nerves is wide in both 
hearing and deaf subjects [Nadol and Xu, 1992]. Nevertheless, our patients achieved significant 
benefit from hearing aid amplification and cochlear implantation [Vermeire et al., 2006] despite 
DFNA9 is known to involve cochlear dendrites. Some limitations of our study should be 
acknowledged. Although the population being referred to our tertiary health care center is quite 
large, the number of identified and enrolled DFNA9 cases is small, reflecting the low-incidence of this 
pathology in the general population [Fransen and Van Camp, 1999; Usami et al., 2003; Chen et al., 
2013]; nonetheless 3 out of 4 enrolled DFNA9 patients belonged to the same family and all the 
patients had long-standing disease with moderate-severe sensorineural hearing loss with vestibular 
hyporeflexia. Thus, our study could not rule out the possibility that clinical and MRI features of EH 
are present exclusively at the onset and in milder phenotypes. Future studies including larger cohorts 
with a broader clinical and genetic spectrum of DFNA9 are warranted to determine early and milder 
imaging phenotypes. We could not provide histological data that would have better explained our 
MR findings, which is another limitation that has to be cited.   
6 Conclusions 
Increased perilymph enhancement on 4hs-delayed postcontrast 3D-FLAIR sequence is the common 
imaging feature of DFNA9 ears, suggesting that BLB breakdown may play the main role in the 
pathophysiology of this disease. In contrast, MR imaging excludes the presence of significant 
hydrops. This finding might be clinically useful in differentiating DFNA9 disease mimicking Ménière’s 
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disease. Based on this report, further studies should evaluate if different DFNA9 mutations show 
similar MRI patterns with 4hs-delayed postcontrast 3D-FLAIR sequence. 
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9. Figure Legends 
Fig. 1. MR findings in two subjects affected by DFNA9 (A,B,C,D) and SSHL (E,F,G,H). (A,E) axial 
precontrast T1 weighted fast spin echo (T1 FSE), (B,F) T2 weighted three-dimensional (3D) steady-
state free precession (FFSP) sequence, (C,G) three-dimensional (3D) Fluid-Attenuated Inversion 
Recovery (FLAIR) sequence and (D,H) 4hs-delayed postcontrast 3D-FLAIR sequence.  
On T1 FSE and 3D-FFSP no signal abnormalities are present in both DFNA9 patient (A,B) and SSHL 
patient (E,F). On pre-contrast 3D-FLAIR sequence, SSHL patient shows mild signal hyperintensity on 
the right affected ear (arrow) indicating proteinaceous content in the perilymph (G), in contrast 
DFNA9 patient shows no signal abnormalities (C). On 4hs-delayed 3D-FLAIR sequence, the SSHL 
patient shows mild enhancement in the affected right ear (dotted arrow) indicating the presence of 
Blood-Labyrinthine Barrier (BLB) breakdown, and no signal abnormalities are present in the left 
healthy ear (H); in contrast the DFNA9 patient shows prominent bilateral enhancement of the inner 
ear (arrow) suggesting bilateral BLB breakdown (D). The metrics calculated in the SSHL patient are 
the follows: T1 cSI -> R 0.6 - L 0.7; T2 cSI -> R 0.7 -  L 0.7 ; FLAIR cSI -> R 4.6 -  L 3.4; Enhancement -> R 
3.3 - L 1.5 . The metrics calculated in the DFNA9 patient are listed in Table 4, patient #4. 
 
Fig. 2. (A) axial T2 weighted three-dimensional (3D) steady-state free precession (FFSP) image taken 
at the level of the cochlea showing position of the hand-drawn region of interest (ROI) contouring 
the middle turn of the cochlea. A second ROI of the same area has been drawn in the 
cerebellopontine angle (CPA) to depict liquor signal intensity (S.I.), used as reference value for 
calculation of signal intensity ratio as described in “Material and Methods” section. (B) axial 4hs-
delayed postcontrast three-dimensional (3D) Fluid-Attenuated Inversion Recovery (FLAIR) image 
taken at the level of the cochlear basal turn and vestibular labyrinth. Image shows the hand-drawn 
region of interest (ROI) contouring the vestibular endolymphatic space (arrow) and the hand-drawn 
ROI contouring the sum of vestibular perilymphatic and endolymphatic space (arrow head) used for 
the quantitative assessment of endolymphatic hydrops as described by Nakashima et al., [2009] 
[Nakashima et al., 2009]. 
 
 
